Nuvectis Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	26.79	18.53	19.13	19.99	5.74	-
Cash & Short-Term Investments	26.79	18.53	19.13	19.99	5.74	-
Cash Growth	47.90%	-3.10%	-4.34%	248.19%	-	-
Other Current Assets	0.21	0.07	0.06	0.41	0.09	-
Total Current Assets	27.01	18.61	19.19	20.41	5.83	-
Long-Term Deferred Charges	-	-	-	-	0.82	-
Total Assets	27.01	18.61	19.19	20.41	6.66	-
Accounts Payable	4.98	2.5	2.77	2.91	1.06	0.01
Accrued Expenses	5.08	6.4	4.21	2.83	0.54	-
Other Current Liabilities	0.08	-	-	0.45	0.82	-
Total Current Liabilities	10.14	8.89	6.98	6.19	2.42	0.01
Total Liabilities	10.14	8.89	6.98	6.19	2.42	0.01
Additional Paid-In Capital	101.78	82.96	66.45	46.2	1.89	-
Retained Earnings	-84.91	-73.25	-54.25	-31.99	-12.9	-0.01
Total Common Equity	16.87	9.71	12.2	14.22	-11.01	-0.01
Shareholders' Equity	16.87	9.71	12.2	14.22	4.24	-0.01
Total Liabilities & Equity	27.01	18.61	19.19	20.41	6.66	-
Net Cash (Debt)	26.79	18.53	19.13	19.99	5.74	-
Net Cash Growth	47.90%	-3.10%	-4.34%	248.19%	-	-
Net Cash Per Share	1.40	1.08	1.23	1.58	1.35	-
Filing Date Shares Outstanding	25.46	23.39	17.77	14.75	12.72	3.9
Total Common Shares Outstanding	23.88	19.5	17.42	14.64	4.51	3.9
Working Capital	16.87	9.71	12.2	14.22	3.41	-0.01
Book Value Per Share	0.71	0.50	0.70	0.97	-2.44	-0.00
Tangible Book Value	16.87	9.71	12.2	14.22	-11.01	-0.01
Tangible Book Value Per Share	0.71	0.50	0.70	0.97	-2.44	-0.00

Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q